References
- UNAIDSUNAIDS report on the Global AIDS epidemic 20132013Accessed March 4, 2015 Available from: http://www.unaids.org/en/resources/campaigns/20121120_globalreport2012/globalreport
- UNAIDSGlobal report 2012: AIDS info 20122012Accessed March 1, 2015 Available from: http://www.unaids.org/en/dataanalysis/datatools/aidsinfo
- UNAIDSGlobal AIDS response progress reporting 20122012Accessed March 1, 2015 Available from http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/document/2011/JC2215_Global_AIDS_Response_Progress_Reporting_en.pdf
- ShetAAntonyJArumugamKKumar DodderiSRodriguesRDeCostaAInfluence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in IndiaPLoS One20149e9102824614165
- d’Arminio MonforteALepriACRezzaGInsights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive PatientsAIDS20001449950710780712
- ChantratitaWKiertiburanakulSSungkanuparphSCharoenyingwattanaAMahasirimongkolSIntegrating HIV-1 pharmacogenomics into the universal coverage health-care system in Thailand: from scientific evidence to policyJ Pharmacogenomics Pharmacoproteomics2011S616
- TozziVPharmacogenetics of antiretroviralsAntiviral Res20108519020019744523
- SukasemCCresseyTRPrapaithongPPharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adultsBr J Clin Pharmacol2012741005101222471906
- ManosuthiWSukasemCLueangniyomkulAImpact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patientsAntimicrob Agents Chemother2013571019102423254426
- SukasemCChamnanphonMKoomdeeNPharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adultsDrug Metab Pharmacokinet20142928929524477223
- CresseyTRLallemantMPharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an updateInfect Genet Evol2007733334217045554
- ClarkeHMousaSAThe implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descentPharmgenomics Pers Med20092939923226038
- HaasDWPharmacogenomics and HIV therapeuticsJ Infect Dis20051911397140015809895
- Department of Disease Control MoPHThailand National Guidelines on HIV/AIDS Treatment and Prevention 2014Thailand2014 Available from: http://www.thaiaidssociety.org/images/PDF/hiv_guideline_2557.pdfAccessed March 1, 2015
- WangsomboonsiriWMahasirimongkolSChantarangsuSAssociation between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimenClin Infect Dis20105059760420073992
- AnanworanichJMoorZSiangphoeUIncidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugsAIDS20051918519215668544
- ChantarangsuSMushirodaTMahasirimongkolSHLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patientsPharmacogenet Genomics20091913914619104471
- MarzoliniCTelentiADecosterdLAGreubGBiollazJBuclinTEfavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patientsAIDS200115717511192870
- KDIGOClinical practice guideline for acute kidney injury 20122012Accessed March 1, 2015 Available from: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO%20AKI%20Guideline.pdf
- LongoDLFauciASKasperDLHauserSLJamesonJLLoscalzoJHarrison’s Principles of Internal Medicine18 edNew YorkMcGraw-Hill2012
- MallalSNolanDWittCAssociation between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirLancet200235972773211888582
- NolanDGaudieriSMallalSPharmacogenetics: a practical role in predicting antiretroviral drug toxicity?J HIV Ther20038364112838163
- PuthanakitTBunupuradahTKosalaraksaPPrevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir usePediatr Infect Dis J20133225225322986704
- PhillipsEJGenetic screening to prevent abacavir hypersensitivity reaction: are we there yet?Clin Infect Dis20064310310516758425
- ParkWBChoePGSongKHShould HLA-B*5701 screening be performed in every ethnic group before starting abacavir?Clin Infect Dis20094836536719115972
- MiddletonDMenchacaLRoodHKomerofskyRNew allele frequency database: http://www.allelefrequencies.netTissue Antigens20036140340712753660